SHARPE
Reported results
- Reported net sales increased 7.7% to $6.5 billion for the quarter.
- Organic net sales increased 7.7% in the quarter.
- Reported operating income margin was 15.9% for the quarter.
- Adjusted operating income margin increased 60 bps to 26.2% in the quarter.
- Reported net earnings per diluted share decreased 11.7% to $1.96 in the quarter.
- Adjusted net earnings per diluted share increased 10.3% to $3.52 in the quarter.
Guidance
- Full year 2026 organic net sales growth is expected to be in the range of 6.5% to 7.0%.
- Full year 2026 adjusted net earnings per diluted share is expected to be in the range of $14.80 to $14.90.
Notes
In the first quarter of 2026, Stryker announced a change in organizational structure combining Orthopaedic Instruments and Other Orthopaedics into Ortho Tech, and Neuro Cranial and Enabling Technologies into Instruments, which has been reflected across all historical periods presented.
Price and volatility reaction
The stock moved -6.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -6.3 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 311.75 | 2026-10-29 |
| Close after release | 291.86 | 2026-10-30 |
| Realised move | -6.4% | close to close |
| 30d ATM IV change | -6.3 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.